Table 1. Characteristics of the patients.
| Characteristics | Value |
|---|---|
| Sex (male/female) - number of patients | 37/19 |
| Age at diagnosis - median [range] | 65 [43–84] |
| Age at study entry - median [range] | 72 [55–88] |
| Binet stage - number of patients (%) | |
| A | 34/55 (60.7%) |
| B | 19/55 (33.9%) |
| C | 3/55 (5.4%) |
| Lymphocytosis (Giga/L) - median (± SEM) | 51.6 (± 6.53) |
| Lymphocyte doubling time - median (months)* | 24 |
| IGHV mutational status - number of patients (%) | |
| Unmutated (≥ 98% homology) | 10/48 (20.8%) |
| Mutated (< 98% homology) | 38/48 (79.2%) |
| CD38 > 30% - number of patients (%) | 14/55 (25%) |
| Cytogenetic risk category - number of patients (%) | |
| Low risk - Isolated del(13q) | 17/55 (30.4%) |
| Intermediate risk- Trisomy 12, normal karyotype and FISH | 15/55 (26.8%) |
| High risk - del(11q), del(17p), complex karyotype | 12/55 (21.4%) |
| Progression free survival - median (months)* | 104 |
| Treatment free survival - median (months)* | 120 |
Abbreviations: IGHV, immunoglobulin heavy chain variable region; FISH, fluorescence in situ hybridization; *, Kaplan-Meyer survival analysis.